Procalcitonin and proinflammatory cytokine interactions in sepsis

Shock

Volumn 12, Issue 4, 1999, Pages 268-273

  Whang, Keven T ^a,b   Vath, Steven D ^b,c   Nylen, Eric S ^b,c   Muller, Beat ^d   Li, Qichang ^e   Tamarkin, Lawrence ^e   White, Jon C ^b,c  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d HARVARD UNIVERSITY   (United States)

^e CytImmune Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; INTERLEUKIN 1; PROCALCITONIN; PROTEIN PRECURSOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; HAMSTER; INFLAMMATION; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; SEPSIS; SYRIAN HAMSTER;

ANIMALS; CALCITONIN; CRICETINAE; INFLAMMATION; INTERLEUKIN-1; MALE; MESOCRICETUS; PROTEIN PRECURSORS; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033208788     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199910000-00004     Document Type: Article

References (31)

1. Parillo, JE, moderator: Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 113:227-242, 1990.
2. Anonymous: Increase in national hospital discharge survey rates for septicemia - United States, 1979-1987. MMWR 39:31-34, 1990.
3. American College of Chest Physicians-Society of Critical Care Conference: Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874, 1992.
4. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 81:1162-1172, 1988.
5. Tracy KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474, 1986.
6. Michie HR, Spriggs DR, Manogue KR et al: Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 104:280-286, 1988.
7. Cannon JG, Tompkins RG, Gelfand JA et al: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161:79-84, 1990.
8. Shapiro L, Gelfand JA: Pathophysiology and therapy. New Horizons 1: 13-22, 1993.
9. Abraham E, Wunderink R, Silverman H: Efficacy and safety of monoclonal antibody to human tumor necrosis factor-alpha in patients with the sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 73:934-941, 1995.
10. Fisher CJ, Dhainut JF, Opal SM, Pribble JP: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind placebo-controlled trial. JAMA 271:1836-1843, 1994.
11. Christman JW, Holden EP, Blackwell TS: Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit Care Med 23:955-961, 1995.
12. Cain BS, Meldrum DR, Harkin AH, McIntyre RC: The physiologic basis for anticytokine clinical trials in the treatment of sepsis. J Am Coll Surg 186:337-351, 1998.
13. Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662-664, 1987.
14. Fiedler VB, Ingo L, Sander E, et al: Monoclonal antibody to tumor necrosis factor-α prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 120:574-588, 1992.
15. Fischer E, Marano MA, VanZee KJ, et al: Interleukin-1 receptor blockade improves survival and hemodynamic performance in E.coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89:1551-1557, 1992.
16. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC: An interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550-552, 1990.
17. Snider RH, Nylen ES, Becker KL: Procalcitonin and its component peptides in systemic inflammation: Immunochemical characterization. J Invest Med 45:552-560, 1997.
18. Rau B, Steinbach G, Gansauge F, et al: The potential role of procalcitonin and interleukin-8 in the prediction of infected necrosis in acute pancreati-tis. Gut 41:832-840, 1997.
19. Lind L, Ljunghall S: Pronounced elevation in circulating calcitonin in critical care patients is related to the severity of illness and survival. Intensive Care Med 21:63-66, 1995.
20. Nylen ES, Snider RH, Thompson KA, Rohatgi PK, Becker KL: Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci 312:12-18, 1996.
21. Carsin H, Assicot M, Feger F, et al: Evolution and significance of circulating procalcitonin levels compared with IL-6, TNFα and endotoxin levels early after thermal injury. Burns 23:218-224, 1997.
22. Whang KT, Steinwald PM, White JC, et al: Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab 83:3296-3301, 1998.
23. Steinwald PM, Whang KT, Becker KL, Snider RH, Nylen ES, White JC, et al: Elevated calcitonin precursor levels are related to mortality in an animal model of sepsis. Crit Care 3:11-16, 1999.
24. Nylen ES, Whang KT, Snider RH, Steinwald, PM, White JC, Becker KL, et al: Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 26: 1001-1006, 1998.
25. Dandona P, Nix D, Wilson MF, et al: Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79:1605-1608, 1994.
26. Dunne JR, Dunkin BJ, Nelson S, White JC: Effects of granulocyte colony stimulation factor in a non-neutropenic rodent model of E. coli peritonitis. J Surg Res 61:348-354, 1996.
27. Asher A, Mule JJ, Reichert CM, Shiloni E, Rosenburg SA: Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138:963, 1987.
28. Fraker DL, Stovroff MC, Merino MJ, Norton JA: Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J Exp Med 168:95-105, 1998.
29. Paciotti GF, Baron D, Tamarkin L, et al: Novel enzyme immunoassays for the detection of the cytokines interleukin 1 and interleukin 2 in the circulation of normal subjects: 24-hour profiles. Prog Neuroendocrinimmunol 5:21-30, 1992.
30. Whiteside TL: Cytokine measurements and interpretation of cytokine assays in human disease. J Clin Immunol 14:327-339, 1994.
31. Bagby GJ, Plessala LA, Wilson LA, Thompson JJ, Nelson S: Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J Infect Dis 163:83-88, 1991.